Death by a thousand cuts. Dilute as a means of using pay as go ATM. Longs will get bill in the end on the reverse split.
Yes he knows something alright, he is going to be cut in half. 15 to 20 is the bottom.
The only hope here is Mnkd can launch on a micro scale and actually create growing cash flow with an innovative product. Then I here the question in the background "....if Sny could not do it, what makes so sure Mnkd can do it?" Mnkd will have to execute, get folks to go to Drs who will readily prescribe.
this does not excuse Paypal from making this stupid decision. Sell this stock now. Elon Musk is gone and you, the shareholder, are not paypal's pal. Instead of trying to be a good company, they are trying to be a crony company. Their eye is not on the ball. Bad sign, and I predict problems ahead for this company.
How about a 25 for 1 stock split and immediate secondary to get this started.
Like to hear news about spin offs to stop the bashing and selling. More value in the parts.
what is the exercise price for these. Looks like they are giving away 10 percent of the company. Nice for the directors.
� a Phase 2 clinical trial initiated in 2013, GS-US-330-0101, or the 0101 trial, investigating GS-4774 in combination with ongoing oral antiviral treatment in patients with chronic HBV infection. The 0101 trial was a multicenter, multinational trial that enrolled 178 patients in a randomized, open-label design comparing three different doses of GS-4774 (2YU, 10YU or 40YU), administered in combination with oral antiviral therapy versus antiviral treatment alone. The primary endpoint for this trial was decline in serum HBV surface antigen, or HBsAg. In May 2015, we announced top line results from this study. Patients treated with the highest dose of GS-4774 plus ongoing oral antiviral therapy, or OAV, did not show a reduction in HBsAg at week 24, the primary endpoint of the study. These study results were presented at The Liver Meeting, November 13-17, 2015 in San Francisco, CA.
� a second Phase 2 clinical trial initiated in 2014, GS-US-330-1401, or the 1401 trial, investigating GS-4774 in patients with chronic HBV infection who are currently not receiving treatment. The 1401 trial is a multicenter, multinational trial designed to enroll 175 patients in a randomized, open-label design comparing three different doses of GS-4774 (2YU, 10YU, or 40YU), administered in combination with tenofovir disoproxil fumarate, or TDF, versus TDF alone. The 1401 trial is fully enrolled. The 24-week results for this trial did not show a statistical difference between control and treatment arms and the 48-week results are projected to be available in the second half of 2016.
Dragging their feet, reluctance, don't have it together yet.
apple could have had I-Cable and all of it: bought Netflix, helped all the networks stream their data so he could put it on his latest coolest device. Networks going to streaming anyway but would have done so faster to get in on the action with Jobs, cut the price of cable and offered limited channels with consumer choice..He would have owned cable and apple would be 1,000 a share, but what do we get, missing revs and earnings. Apple without Jobs is like everybody else..
If they BK and only get rid of half the debt, Dxm will still be wrong. They will BK yet again later. I would liquidate this pos.
If no news, I think you don't get a 2.53 price so that you can cover and get your money back. This story still has two weeks to churn. Volume on Friday was historic for this company. It blew all previous active days out of the water by a mile. Insiders are holding tight as a drum. Nano caps were active Friday, but this one went way out there. Be good to see who is doing all this big buying.
I really hope you are right wbar. I was looking at it this way: Drug was a flop at 24 weeks in. So why doesn't GILD pull the plug on this? It didn't work in the chronic end and so far not in the 24 week naive study either, but it did work in healthy individuals. GILD must see something or just throwing good money after bad. No real press release about the 24 week failure just a roll over report to 48 weeks and last half of the year. I sure hope the value of 4774 is more than zero.
Why did insiders stop selling since March? Something stopped them. Be careful..
Insiders are holding and available shares are in newer stronger hands. You better hope there isn't any news on the other side of this volume action today.